Abstract:Introduction: Japanese encephalitis virus (JEV) and Zika virus (ZIKV) pose a severe threat to human health. Our previous research results, as well as those of other research groups, indicated that antibodies (Abs) induced by JEV infection or JEV vaccine vaccination could enhance ZIKV infection in vitro and exacerbate the mortality of ZIKV-infected mice, vice versa, which is known as antibody-dependent enhancement (ADE). Although studies on other flaviviruses revealed that altering the amino acid residues located in the fusion loop (FL) of envelope (E) protein can reduce the level of flavivirus-cross-reactive Abs, thereby abating the ADE of heterologous flavivirus infection, it is unclear whether this strategy is equally applicable to JEV. Methods: In this study, we constructed recombinant adenoviruses and nucleotide-modified mRNA-lipid nanoparticle (LNP) encoding JEV wild-type E protein or E protein mutant (designated as Ad5-JEV-E WT and Ad5-JEV-E mut ; JEV-E WT mRNA-LNP, and JEV-E mut mRNA-LNP). We evaluated the immunogenicity of these vaccine candidates in mice and the capacity of vaccine-immune mouse sera to neutralize JEV infection or mediate ADE of ZIKV infection in vitro and in vivo . Results: Ad5-JEV-E mut or JEV-E mut mRNA-LNP immunization induced ZIKV-cross-reactive Ab response which is dramatically lower than that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The levels of JEV-neutralizing Abs induced by Ad5-JEV-E mut or JEV-E mut mRNA-LNP are comparable to that induced by Ad5-JEV-E WT and JEV-E WT mRNA-LNP, respectively. The ability of Abs induced by Ad5-JEV-E mut to enhance ZIKV infection in vitro is attenuated as compared with that induced by Ad5-JEV-E WT . Moreover, JEV-E mut mRNA-LNP immunization elicited potent T cell response similar to JEV-E WT mRNA-LNP in mice. Mice immunized with each mRNA-LNP exhibited lower level of serum viral load than the mock-immunized mice post JEV challenge. Mice receiving JEV-E WT mRNA-LNP-immune mouse sera exhibited ADE post ZIKV challenge whereas passively transferred JEV-E mut mRNA-LNP-immune mouse sera did not lead to obvious ADE of ZIKV infection in recipient mice. Most importantly, maternally acquired Abs did not enhance the mortality of 1-day-old neonates born to JEV-E mut mRNA-LNP-immunized mice post ZIKV challenge. Discussion: These results suggest that optimizing the FL sequence of JEV could significantly reduce the level of JEV/ZIKV-cross-reactive Abs and abrogate the ADE of ZIKV infection, providing a promising strategy to develop effective and safety JEV vaccine.

Japanese encephalitis virus JEV replicon vector and application thereof

Construction and Identification of a Vector Inserted with Gene of T7 RNA Polymerase

A highly pathogenic porcine reproductive and respiratory syndrome virus candidate vaccine based on Japanese encephalitis virus replicon system

Generation and characterization of a new mammalian cell line continuously expressing virus-like particles of Japanese encephalitis virus for a subunit vaccine candidate

Engineering the Japanese encephalitis virus RNA genome for the expression of foreign genes of various sizes: Implications for packaging capacity and RNA replication efficiency

Construction of Cell Line Stably Expressing IBDV VP2 Protein Mutants

Insights into the Pathogenesis and Development of Recombinant Japanese Encephalitis Virus Genotype 3 as a Vaccine

The Safety and Immunity at a Recombinant Pseudorabies Virus Expression NS_(1) Protein of Japanese Encephalitic Virus

An engineered Japanese encephalitis virus mRNA-lipid nanoparticle immunization induces protective immunity in mice

Construction of Recombinant Virus Strain TK~-/gG~-/PrM~+ Recombinized by Pseudorabies Virus Ea Mutant Strain TK~-/gG~-/LacZ~+ and PrM Gene of Japanese Encephalitis Virus

Generation and characterization of Japanese encephalitis virus expressing GFP reporter gene for high throughput drug screening

Complete protection for mice conferred by a DNA vaccine based on the Japanese encephalitis virus P3 strain used to prepare the inactivated vaccine in China

Development of an RNA virus-based episomal vector with artificial aptazyme for gene silencing

Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets

A Lentiviral Vector Expressing Japanese Encephalitis Virus-like Particles Elicits Broad Neutralizing Antibody Response in Pigs

Production of Japanese encephalitis virus-like particles in insect cells

Mutation of Putative N-linked Glycosylation Sites in Japanese Encephalitis Virus Premembrane and Envelope Proteins Enhances Humoral Immunity in BALB/C Mice after DNA Vaccination.

Japanese encephalitis genotype I virus-like particles stably expressed in BHK-21 cells serves as potential antigen in JE IgM ELISA

Construction of Genes Encoding Structure Proteins Derived from Japanese Encephalitis Virus

[Construction of a full-genome HCV replicon with self-cleaving double ribozyme sequences and characterization in vitro and in vivo]

Infectious subgenomic amplicon strategies for Japanese encephalitis and West Nile viruses